{"text": "TITLE:\n      A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults\nSUMMARY:\n      This study compares the safety and immunogenicity profile of several travel vaccines given\n      alone or concomitantly with MenACWY-CRM to healthy adults.\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n        Female and male subjects who must be healthy and must be:\n          1. Between 18 and 60 years of age inclusive and who have given their written informed\n             consent;\n          2. Available for all visits and telephone calls scheduled for the study;\n          3. In good health as determined by medical history, physical examination and clinical\n             judgment of the investigator;\n          4. For female subjects, having a negative urine pregnancy test.\n        Exclusion Criteria:\n        Individuals not eligible to be enrolled in the study are those:\n          1. who are breastfeeding;\n          2. who have a personal history of Neisseria meningitidis infection, typhoid fever,\n             rabies, or any flavivirus infection (e.g., Japanese encephalitis, tick-borne\n             encephalitis, yellow fever, dengue fever, West Nile virus infection);\n          3. who have been immunized with any of the study vaccines within the last five years as\n             determined by medical history and/or vaccination card;\n          4. who have received investigational agents or vaccines within 30 days prior to\n             enrollment or who expect to receive an investigational agent or vaccine prior to\n             completion of the study;\n          5. who have received live licensed vaccines within 30 days and inactive vaccine within\n             15 days prior to enrollment or for whom receipt of a licensed vaccine is anticipated\n             during the study period.\n             (Exception: Influenza vaccine may be administered up to 15 days prior to each study\n             immunization and no less than 15 days after each study immunization);\n          6. who have received an anti-malaria drug, up to 2 months prior to the study;\n          7. who have experienced, within the 7 days prior to enrollment, significant acute\n             infection (for example requiring systemic antibiotic treatment or antiviral therapy)\n             or have experienced fever (defined as body temperature \u2265 38\u00b0C) within 3 days prior to\n             enrollment;\n          8. who have any serious acute, chronic or progressive disease such as:\n               -  history of cancer\n               -  complicated diabetes mellitus\n               -  advanced arteriosclerotic disease\n               -  autoimmune disease\n               -  HIV infection or AIDS\n               -  blood dyscrasias\n               -  congestive heart failure\n               -  renal failure\n               -  severe malnutrition (Note: Subjects with mild asthma are eligible for\n                  enrollment. Subjects with moderate or severe asthma requiring routine use of\n                  inhaled or systemic corticosteroids are not eligible for enrollment);\n          9. who have epilepsy, any progressive neurological disease or history of Guillain-Barre\n             syndrome;\n         10. who have a history of anaphylaxis, serious vaccine reactions, or allergy to any\n             vaccine component, including but not limited to latex allergy, egg allergy,\n             antibiotic allergy, chicken proteins or gelatin allergy;\n         11. who have a known or suspected impairment/alteration of immune function, either\n             congenital or acquired or resulting from (for example):\n               -  receipt of immunosuppressive therapy within 30 days prior to enrollment\n                  (systemic corticosteroids administered for more than 5 days, or in a daily dose\n                  > 1 mg/kg/day prednisone or equivalent during any of 30 days prior to\n                  enrollment, or cancer chemotherapy);\n               -  receipt of immunostimulants;\n               -  receipt of parenteral immunoglobulin preparation, blood products, and/or plasma\n                  derivatives within 90 days prior to enrollment and for the full length of the\n                  study;\n         12. who are known to have a bleeding diathesis, or any condition that may be associated\n             with a prolonged bleeding time;\n         13. who have myasthenia gravis; thyroid or thymic disorders,\n         14. who have any condition that, in the opinion of the investigator, might interfere with\n             the evaluation of the study objectives;\n         15. who are part of the study personnel or close family members of those conducting this\n             study.\n         16. for whom a long-term stay (\u2265 1 month) was planned in Africa, Latin America, or Asia.\n", "cuis": "C0220825 C0042210 C0042196 C2003457 C1522485 C1705425 C0947630 C3897779 C1552616 C1706244 C0042210 C1555670 C0947630 C3244317 C2003457 C0686750 C0243161 C0013893 C0243161 C3244317 C0562357 C0947630 C0302186 C0086960 C1512346 C0031809 C0944752 C0946068 C2973270 C1444322 C1444324 C0262926 C0422836 C0455458 C3272565 C0022423 C0430056 C0373524 C0593623 C2188702 C0518505 C0522772 C1548746 C1513916 C0243161 C1555471 C0947630 C0006147 C1623040 C1623041 C0523282 C1294231 C2026659 C0262926 C0424945 C0041466 C0030528 C0009450 C3714514 C0275524 C0012683 C0035637 C0276041 C0729555 C0747002 C0014057 C0771080 C3536988 C3714691 C0009450 C3714514 C0275524 C0012683 C0035637 C0276041 C0729555 C0747002 C0034494 C0043124 C1096184 C0014038 C1112174 C1403937 C1409206 C0206019 C0276548 C0238097 C0276226 C0751445 C1402829 C0043395 C0301508 C0239574 C0011311 C1548477 C0042210 C0947630 C0262926 C0422836 C0455458 C0042196 C2713304 C0058773 C0419749 C3245491 C1552578 C0013230 C0220825 C1261322 C0042210 C3842337 C0013230 C3888021 C1516879 C0042210 C0947630 C0042210 C3244313 C3834263 C3842337 C1548573 C3888021 C1516879 C0042210 C3840775 C1548573 C0025344 C0947630 C0021403 C2708137 C1717123 C0042200 C0947630 C0020971 C0042196 C0496628 C2987227 C0302020 C0042200 C0199804 C0199808 C0199810 C0849707 C0850113 C0948201 C1656594 C0947630 C0024530 C0206255 C1744563 C0947630 C0013227 C1254351 C3843731 C3888021 C1516879 C0237607 C0596545 C3845885 C0280274 C1563738 C0003232 C0377919 C0003237 C3540704 C3540705 C3540706 C3540707 C3540708 C3540709 C3540710 C0009450 C3714514 C0275524 C0012683 C0035637 C0276041 C0729555 C0747002 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0015967 C0424755 C0152338 C0237607 C0596545 C3845885 C0886414 C3888021 C1516879 C0677932 C1335499 C4013160 C0262926 C2004062 C0006826 C0260515 C0342257 C0012634 C0018609 C0004364 C0406632 C0400936 C0850560 C0577642 C0687719 C0019693 C3669463 C0276500 C0276501 C0018939 C0018802 C0264719 C0264722 C0742758 C2039715 C0035078 C0001623 C1963154 C3267129 C3810103 C1167727 C0311276 C0267981 C0004096 C1316572 C1317574 C0581126 C3888021 C1516879 C1547226 C4049705 C4049706 C0001617 C3653466 C3539185 C3540725 C3540726 C3540727 C3536709 C0161508 C0239126 C1555471 C3888021 C1516879 C0004048 C0027765 C0042075 C0752235 C0014544 C0262926 C2004062 C0018378 C3839460 C0039082 C0206064 C0796095 C0796110 C2936859 C2936904 C0002792 C0850803 C0262926 C2004062 C0042210 C0020517 C0489531 C1527304 C0719113 C0719656 C3247823 C0000828 C0442740 C0577628 C1998401 C0917921 C1443619 C0559469 C0042210 C1524073 C3834249 C4049609 C4049610 C4050368 C0741103 C0017237 C0020517 C0489531 C1527304 C0719113 C0719656 C3247823 C0684336 C3845945 C2598156 C0031843 C1705273 C0076106 C3845898 C3245488 C0021079 C0455630 C3888021 C1516879 C3842337 C0001617 C3653466 C3539185 C3540725 C3540726 C3540727 C3536709 C0161508 C0239126 C3842480 C0032952 C0065967 C1561538 C3842337 C0392920 C3665472 C3888021 C1516879 C0001551 C0257585 C3653857 C0021027 C0020843 C0020852 C0202081 C0481219 C0085297 C0553533 C2748351 C0202083 C2825347 C0577612 C0202086 C0202087 C3536873 C0202084 C0201467 C0850992 C0456388 C0030547 C2359959 C0032105 C0071888 C0040165 C0041014 C0528271 C0608117 C0036679 C3888021 C1516879 C3842337 C0606968 C0947630 C0005779 C1458140 C0012634 C3864998 C0009647 C0871117 C3845898 C0019080 C0151872 C0151878 C0026896 C0012634 C0007222 C0017178 C0040132 C0040134 C2228489 C0076638 C0117002 C0012634 C3864998 C0009647 C0871117 C0871010 C0220825 C1261322 C1444296 C1444299 C0018017 C2239270 C0947630 C0947630 C0034770 C0947630 C1561542 ", "concepts": "Evaluate, Vaccines, Vaccine, MenACWY, Label, Label, Study, Randomiz summary, summary vaccines, travel, study, given MenACWY, healthy adult criteria, Eligibility Criteria given, Uninformed study, telephone call, schedule, visit rnrx physical examination, Eye physical examination, Eye physical examination, Annual physical examination, Assess physical examination, Manage physical examination, medical history, No medical history, Past medical history, Clinical judgment Urine pregnancy test, Urine pregnancy test, urine home pregnancy test, urine hCG, pregnancy test, shaving, shaving, Shaving, Negative Criteria not eligible, study breastfeedings, Breastfeeding, Breastfeeding Neisseria meningitidis, Neisseria meningitidis culture, CSF PCR Neisseria meningitidis, personal history, personal history, typhoid fever, Paratyphoid fever, Infection, infections, Coinfections, Disinfection, RP infection, MG infection, GI infection, op infection JE - Japanese encephalitis, Japanese encephalitis, Japanese encephalitis SC, Japanese encephalitis vaccine, Infection, infections, Coinfections, Disinfection, RP infection, MG infection, GI infection, op infection, rabies West Nile virus infection, West Nile viral infection, encephalitis, Panencephalitis, mesencephalitis, parencephalitis, encephalitis HIV, HIV encephalitis, cmv encephalitis, encephalitis hsv, Poliencephalitis, leukencephalitis, Yellow fever, yellow fever, low fever, Dengue fever, dengue fever vaccines, study medical history, No medical history, Past medical history, vaccination, Revaccinations, DT vaccination, vaccination dt investigational, investigation, investigational drug, Investigation, Investigation, vaccines, 0 days investigational agent, enrollment, Enrollment, vaccine study vaccine, inactive, Inactive, 0 days, Licensed enrollment, Enrollment, vaccine, Anticipated, Licensed period, study Influenza virus vaccine, Influenza vaccine, Influenza vaccine Set, Influenza vaccination, study immunizations, immunization, immunization, De-immunization, Isoimmunization, flu immunization, BCG immunization, dpt immunization, mmr immunization, CDT immunization, ADT immunization, alloimmunization, DTP immunization, study malarias, malaria, malari, study, drug, drug, 1 to 2 months enrollment, Enrollment, experience, experience, Inexperience antiviral therapy, viral therapy, antibiotics, antibiotic Y, Antibiotics, Antibiotics, Antibiotics, Antibiotics, Antibiotics, Antibiotics, Antibiotics, Antibiotics, Infection, infections, Coinfections, Disinfection, RP infection, MG infection, GI infection, op infection, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment fevers, fever, body, experience, experience, Inexperience, Temperature enrollment, Enrollment progressive disease, Progressive disease, Slowly progressive disease history, history, cancers, cancer complicated diabetes disease, h disease autoimmune disease, autoimmune diseases skin, autoimmune disease liver, other autoimmune disease, FH: Autoimmune disease, Autoimmune disease NEC HIV infection NOS, FIV infection, HIV I infection, HIV 2 infection blood dyscrasias CHF - Congestive heart failure, Acute congestive heart failure, Chronic congestive heart failure, congestive heart failure symptom, systolic congestive heart failure renal failure, Adrenal failure, Renal failure, Prerenal failure, No renal failure, Postrenal failure Severe malnutrition NOS, Oth severe malnutrition, asthma, Note, Note severe asthma, enrollment, Enrollment, Moderate, Moderate, Moderate corticosteroid, Anticorticosteroids, Corticosteroids, Corticosteroids, Corticosteroids, Corticosteroids, Corticosteroid, Pois-corticosteroids, corticosteroid use, not eligible, enrollment, Enrollment, inhaled neurological disease, urological disease, neurological lyme disease, epilepsy, history, history, Guillain-Barre\u0301, Nonprogressive syndrome, syndrome X, syndrome c, W syndrome, N syndrome, G syndrome Anaphylaxis, Anaphylaxis, history, history, vaccine, allergy, allergy, allergy, Callergy, dallergy, Dallergy, Abreactions, No reactions Latex allergy, latex allergy, Hx-latex allergy, No latex allergy, egg allergy, vaccine, Component, Unlimited, Unlimited, Unlimited, Unlimited antibiotic allergy, gelatin, allergy, allergy, allergy, Callergy, dallergy, Dallergy impairment, No impairment, Impairments, function, Function, teration, Uknown acquired Immunosuppressive therapy, NOS, H/O: immunosuppressive therapy, enrollment, Enrollment, 0 days corticosteroid, Anticorticosteroids, Corticosteroids, Corticosteroids, Corticosteroids, Corticosteroids, Corticosteroid, Pois-corticosteroids, corticosteroid use, More than 50 prednisone, meprednisone, day, 0 days Cancer chemotherapy, cancer chemotherapy, enrollment, Enrollment immunostimulants, immunostimulant SRE, Other immunostimulants immunoglobulins, Immunoglobulin D, Immunoglobulin G, Immunoglobulins, Immunoglobulin, IV immunoglobulin, low immunoglobulin, CSF immunoglobulin, Immunoglobulin A, Immunoglobulin A, Immunoglobulin D, Immunoglobulin E, Immunoglobulin G, Immunoglobulin G, Immunoglobulin M, immunoglobulin type, immunoglobulin test, blood products, parenteral, Parenteral, plasma, h preparation, T4 preparation, T3 preparation, preparation LB, preparation 31, Separation enrollment, Enrollment, 0 days, derivative V study bleeding diathesis, Bleeding diathesis, condition, Condition, conditioning, precondition, Uknown bleeding, PT prolonged, QT prolonged myasthenia gravis, disorders, CV disorders, GI disorders, thyroids, thyroid, thyroid, thyroidin, Euthyroid condition, Condition, conditioning, precondition, opinion Evaluation, Evaluation, OT evaluation, Pt evaluation, objective, objective, study study, remembers study month "}
